City of Hope provides cancer support services to Amazon employees

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope announced a partnership to provide a range of enhanced cancer support services to Amazon employees in the U.S.—including a dedicated phone line staffed by oncology nurses, specialized support for complex cancers and diagnosis and treatment plan review.

Amazon employs more than 275,000 people across the U.S.

The services include:

  • Cancer Support Line
    Whether an employee has a question about the side effects of treatment or needs emotional support, a dedicated team of cancer care nurses is available to answer questions and provide information. Employees can call about their own diagnosis or if a family member is diagnosed with cancer.

  • Expert Review
    Employees can benefit from this subspecialized expertise in their own communities by requesting that a City of Hope physician review their diagnosis and treatment plan and provide a written recommendation to the patient’s treating physician regarding the clinical appropriateness of the proposed therapeutic approach. If appropriate, City of Hope physicians will recommend improvements to the proposed treatment plan, including recommendations for–and interpretation of–genetic/genomic testing, identification of potential clinical trials and therapeutic options. An employee may also choose to go to City of Hope for an in-person evaluation with its premier physicians.

  • City of Hope Accountable Precision Oncology Program
    City of Hope specialists work with Amazon’s health plans to support the care of patients with the most complex cancers. City of Hope cancer experts directly engage local primary oncologists to provide a recommendation for appropriate genetic testing and accurate interpretation of test results and advice for optimal treatment, including the appropriate use of the most leading edge, targeted therapies.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login